News | December 19, 2008

UC Davis Refines Radiation Therapy to Reduce Nerve Damage

December 19, 2008 — While radiation treatments deliver precise doses of high-energy X-rays to stop cancer cells from spreading or to shrink tumors, oncologists have become increasingly concerned about inadvertent exposures during head and neck cancer treatments to nerves responsible for upper body mobility. To reduce the possibility of permanent nerve damage, UC Davis Cancer Center researchers have taken the lead in establishing new treatment guidelines for physicians nationwide.

The team, led by Allen Chen, assistant professor of radiation oncology, noticed a trend following treatment for cancers of the tonsil, tongue, throat, and other head and neck organs: A number of patients reported ongoing weakness and sensation problems in their necks, shoulders and upper arms. Chen recognized that these symptoms could be attributed to injury of the brachial plexus nerves, which begin at the back of the neck and extend behind the clavicle and down to the hand. Specific standards for delivering radiation treatments and avoiding this critical body structure, however, did not exist.

"Radiation is an essential treatment for most head and neck cancers, and current technologies make it possible for us to successfully target those tumors," said Chen. "Exposure to other tissues is unavoidable and typically not considered serious or long-term. But brachial plexus damage can be permanent and debilitating, so we decided to develop treatment guidelines to reduce radiation exposure to these nerves."

As a result, Chen and his colleagues established step-by-step techniques for identifying the brachial plexus complex using common anatomical "bench posts" that are easily visible with computed tomography (CT) scans commonly used for treatment planning. He then designed delivery contours for intensity-modulated radiation therapy (IMRT) treatments to avoid those areas, and tested the guidelines on 10 patients with a variety of head and neck cancers.

Outcomes of the study show that the guidelines, which are published in the December 2008 issue of the International Journal of Radiation Oncology, Biology and Physiology, can be used to evaluate the exact radiation doses delivered to the brachial plexus as well as potentially reduce exposures to levels that meet current medical standards. Patients in the study will continue to be monitored for upper body mobility symptoms and to determine if their radiation treatments were as effective as those delivered prior to the new guidelines.

Chen will next refine the guidelines for patients whose anatomies are distinct due to medical treatments or who may have alternate brachial plexus pathways. For some people, for instance, these nerves begin at a slightly lower or higher point in the neck.

"Not all patients have the same body structures, and we will be adding to the recommendations to account for those differences," Chen said. "Our goals are to lessen the impact of cancer treatments as much as possible, and we are committed to taking a leadership role in making sure that radiation treatments for cancer are as safe, effective and comfortable as possible."

Other investigators on the study were William Hall, Michael Guiou, Samir Narayan, Arthur Dublin, Srinivisan Vijayakumar and James Purdy of UC Davis; and Nancy Lee of Memorial Sloan-Kettering Cancer Center.

Source: News from UC Davis Health System

For more information: www.ucdmc.ucdavis.edu

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Northern Centre for Cancer Care (NCCC)

Northern Centre for Cancer Care (NCCC).

Sponsored Content | Case Study | Radiation Therapy | July 05, 2018
Established in 2009, Northern Centre for Cancer Care (NCCC) is the largest center of its kind in the north of England....
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Overlay Init